ANI Pharmaceuticals Financial Statements
NASDAQ: ANIPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ANI Pharmaceuticals revenue and earnings
In fiscal 2025, ANI Pharmaceuticals generated $883.4 million in revenue, up 43.8% from fiscal 2024, its 14th consecutive year of revenue growth. Net income was $78.3 million, for a net margin of 8.9% versus a median of -10.8% in the prior 5 years. Gross margin was 61.4% (up from 59.3%) and operating margin 12.6%.
Diluted earnings per share came in at $3.32. Over the last 5 fiscal years, ANIP's revenue has grown at a 33.5% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
ANI Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 883.37M | 614.38M | 486.82M | 316.38M | 216.14M | 208.47M | 206.55M | 201.58M | 176.84M | 128.62M |
| Revenue growth (YoY) | +43.78% | +26.20% | +53.87% | +46.38% | +3.67% | +0.93% | +2.47% | +13.99% | +37.49% | +68.53% |
| Cost of Revenue | 341.31M | 250.21M | 181.51M | 138.78M | 100.61M | 87.16M | 63.15M | 73.02M | 79.03M | 48.78M |
| Gross Profit | 542.06M | 364.17M | 305.30M | 177.60M | 115.53M | 121.32M | 143.39M | 128.55M | 97.81M | 79.84M |
| Operating Expenses | 430.96M | 363.58M | 258.33M | 212.88M | 155.32M | 137.33M | 127.04M | 93.19M | 69.48M | 59.76M |
| Research & Development | 51.66M | 44.58M | 34.29M | 22.32M | 11.37M | 16.00M | 19.81M | 15.39M | 9.07M | 2.91M |
| Selling, General & Admin | 317.75M | 249.64M | 161.70M | 124.04M | 84.29M | 64.99M | 55.84M | 44.06M | 31.58M | 27.83M |
| Operating Income | 111.09M | 584.00K | 46.97M | -35.28M | -39.79M | -16.02M | 16.35M | 35.36M | 28.33M | 20.08M |
| Interest Expense | 32.56M | 33.63M | 35.63M | 28.51M | 11.95M | 9.48M | 13.47M | 14.91M | 11.32M | 11.29M |
| Other Income (Expense) | 1.93M | -4.03M | -159.00K | 670.00K | -4.34M | -494.00K | -228.00K | -550.00K | 55.00K | -74.00K |
| Pretax Income | 95.79M | -22.21M | 19.87M | -62.66M | -56.06M | -25.96M | 3.16M | 20.05M | 16.35M | 8.68M |
| Income Tax | 17.45M | -3.69M | 1.09M | -14.77M | -13.46M | -3.41M | -2.94M | 4.56M | 17.43M | 4.74M |
| Net Income | 78.34M | -18.52M | 18.78M | -47.90M | -42.60M | -22.55M | 6.09M | 15.49M | -1.08M | 3.93M |
| Net Income growth (YoY) | — | -198.63% | — | — | — | -470.00% | -60.67% | — | -127.35% | -74.41% |
| EPS (Basic) | 3.50 | -1.04 | 0.86 | -3.05 | -3.40 | -1.88 | 0.51 | 1.31 | -0.09 | 0.34 |
| EPS (Diluted) | 3.32 | -1.04 | 0.85 | -3.05 | -3.40 | -1.88 | 0.50 | 1.30 | -0.09 | 0.34 |
| Shares Outstanding (Basic) | 20.05M | 19.32M | 18.00M | 16.26M | 12.60M | 11.96M | 11.84M | 11.68M | 11.55M | 11.45M |
| Shares Outstanding (Diluted) | 21.23M | 19.32M | 18.19M | 16.26M | 12.60M | 11.96M | 12.04M | 11.77M | 11.55M | 11.57M |
| EBITDA | 202.51M | 68.31M | 106.76M | 21.69M | 7.46M | 28.62M | 60.96M | 69.10M | 56.26M | 42.42M |
| Gross Margin | 61.36% | 59.27% | 62.71% | 56.13% | 53.45% | 58.19% | 69.42% | 63.77% | 55.31% | 62.07% |
| Operating Margin | 12.58% | 10.00% | 9.65% | -11.15% | -18.41% | -7.68% | 7.92% | 17.54% | 16.02% | 15.61% |
| Net Margin | 8.87% | -3.01% | 3.86% | -15.14% | -19.71% | -10.82% | 2.95% | 7.69% | -61.00% | 3.06% |
This table shows 10 annual periods of ANI Pharmaceuticals's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ANIP's reporting calendar. What is a income statement?